Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Accumulated Expenses (2016 - 2025)

ImmunityBio (IBRX) has disclosed Accumulated Expenses for 12 consecutive years, with $46.8 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 15.42% to $46.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.8 million through Dec 2025, up 15.42% year-over-year, with the annual reading at $46.8 million for FY2025, 15.42% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $46.8 million at ImmunityBio, up from $43.6 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $64.9 million in Q3 2023, with the low at $27.9 million in Q1 2025.
  • Average Accumulated Expenses over 5 years is $45.7 million, with a median of $43.6 million recorded in 2024.
  • The sharpest move saw Accumulated Expenses skyrocketed 600.73% in 2021, then plummeted 43.3% in 2024.
  • Over 5 years, Accumulated Expenses stood at $51.4 million in 2021, then fell by 18.61% to $41.8 million in 2022, then grew by 2.11% to $42.7 million in 2023, then fell by 4.98% to $40.6 million in 2024, then rose by 15.42% to $46.8 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $46.8 million, $43.6 million, and $35.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.